Dr. Dan Egan

For the Media

Dr. Dan Egan

Dr. Dan Egan is an assistant member of Fred Hutch's Clinical Research Division. He is a medical oncologist and hematologist,with expertise is in the diagnosis and management of benign and malignant hematologic disorders as well as solid tumors. Dr. Egan specializes in the use autologous or allogeneic hematopoietic stem cell transplantation (HSCT) to treat patients with hematologic disorders.

Resources for more information

  • Overview of Daniel Egan’s Research Focus
    Dr. Egan is actively focused on developing immune-based approaches to prevent and treat relapse of myeloid cancers, including after allogeneic HSCT. He is conducting a retrospective study of clinical and biologic factors that may determine responses to donor lymphocyte infusions in patients with post-transplant relapse of AML.
  • Daniel Egan – UWMedicine Profile
    Appointments, affiliations and researcher interests.
  • Program in Immunology
    Program researchers continue to develop ways to make immunity-boosting therapies even more effective. They are showing these treatments can induce remissions for patients with advanced tumors and are likely to have broad utility across many cancers. 


Hutch Team

For more information or to arrange an interview, please contact Fred Hutch at (206) 667-2210 or email our media relations team.


Photos / Graphics / Video


Download photos of Dan Egan

Related Stories

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch’s pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation’s first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women’s Health Initiative and the international headquarters of the HIV Vaccine Trials Network.